Markets

HeartBeam Completes Enrollment Ahead Of Schedule In 486-Patient HEADSTART-ACS Study

Oct 21, 2026 · 08:40 AM ET· updated 1h ago

HEADSTART-ACS study conducted in collaboration with Indonesia’s National Cardiovascular Center in world’s fourth most populous country, representing strategically significant market of 288 million peopleData analysis is

Why It Matters

HeartBeam finished signing up patients faster than expected for a heart study. When a company moves ahead of schedule, it can mean their product is working well and they are on track.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

BEAT0.41

+0.00 (+0.73%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.